Using myeloma as an example, why trial representativeness has a meaningful clinical impact in oncology DETERMINATION trial: https://www.nejm.org/doi/full/10.1056/NEJMoa2204925 Blood letter:…
A story of two antibody drug conjugate payloads
How I think agents should be sequenced in HER2 mutant lung cancer. Case report on zongertinib upregulating HER2 receptors: https://pmc.ncbi.nlm.nih.gov/articles/PMC12964209/
Why did we start using an anti-seizure medication for ICANS? Study on levetiracetam: https://ashpublications.org/bloodadvances/article/9/21/5501/546533/Routine-prophylaxis-with-levetiracetam-offers-no
Thoughts on the HER2 3+ and HER2 2+/ISH+ subgroups for zanidatamab, and its mechanism of action JACOB trial: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30481-9/abstract…
How ESR1 mutations develop in breast cancer, targeting them, and some differences between elacestrant, imlunestrant, and vepdegestrant
Explaining CELMoDs. It's hard to pronounce ubiquitination! JCO article on VTE events in clinical trials: https://ascopubs.org/doi/10.1200/JCO-25-00489
With lurbinectedin being withdrawn from second line extensive stage small cell lung cancer, thoughts on what treatments have been effective in this aggressive cancer.
Problems with how we currently test for HER2 and possible future directions. Trastuzumab in endometrial cancer: https://pmc.ncbi.nlm.nih.gov/articles/PMC8792803/Issues with HER2 testing in endometrial…
Podcast on the changing definition of chemotherapy resistance French small cell lung cancer trial: https://pubmed.ncbi.nlm.nih.gov/32888454/ Platinum resistance in endometrial cancer (Japan):…
